FAQ: Quantum BioPharma Ltd. Clarifies Name, Ownership, and RTO Rumors
Summary
What is the main topic of the press release from Quantum BioPharma Ltd.?
The press release clarifies misinformation regarding a name change and reverse takeover (RTO) involving Unbuzzd Wellness Inc., confirming Quantum BioPharma has not changed its name to unbuzzd and is not involved in an RTO transaction.
Why is Quantum BioPharma’s clarification important?
This clarification is important to correct misinformation circulating on social media and stock trading platforms, ensuring investors and the public have accurate information about the company’s name, ownership, and financial dealings.
How is Quantum BioPharma related to Unbuzzd Wellness Inc.?
Quantum BioPharma is Unbuzzd’s largest shareholder and debt holder, holding 200 million shares of unbuzzd, a 7% royalty agreement on revenue up to $250 million, and a warrant to expand its stake to 25%, alongside a $1.3 million loan at 10% interest over three years.
Who leads Unbuzzd Wellness Inc.?
Unbuzzd is led by former Coca-Cola executive John Duffy and Celsius Holdings’ former CEO Gerry David, and is preparing for a possible IPO with MNP LLP conducting PCAOB audits.
What financial agreement did Quantum BioPharma announce?
Quantum BioPharma announced a pending $20,930 debt settlement with two vendors, to be completed in early June.
What does Quantum BioPharma specialize in?
Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, with a lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation in multiple sclerosis.
Where can investors find the latest news and updates about Quantum BioPharma Ltd.?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/.
What is the significance of the royalty agreement between Quantum BioPharma and Celly Nutrition?
The royalty agreement ensures Quantum BioPharma receives 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity, while retaining rights to develop similar products for pharmaceutical and medical uses.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 110429